QNCX vs. ATRA, VSTM, VTGN, SELB, OPT, CLLS, MOLN, VXRT, CRDF, and LIFE
Should you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Atara Biotherapeutics (ATRA), Verastem (VSTM), Vistagen Therapeutics (VTGN), Selecta Biosciences (SELB), Opthea (OPT), Cellectis (CLLS), Molecular Partners (MOLN), Vaxart (VXRT), Cardiff Oncology (CRDF), and aTyr Pharma (LIFE). These companies are all part of the "medical" sector.
Quince Therapeutics (NASDAQ:QNCX) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.
30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 16.8% of Quince Therapeutics shares are held by insiders. Comparatively, 3.7% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Quince Therapeutics has higher earnings, but lower revenue than Atara Biotherapeutics. Quince Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Atara Biotherapeutics has a consensus price target of $28.00, suggesting a potential upside of 5,193.01%. Given Atara Biotherapeutics' higher possible upside, analysts clearly believe Atara Biotherapeutics is more favorable than Quince Therapeutics.
In the previous week, Atara Biotherapeutics had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 2 mentions for Atara Biotherapeutics and 1 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.00 equaled Atara Biotherapeutics'average media sentiment score.
Quince Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
Quince Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -671.70%. Quince Therapeutics' return on equity of -36.72% beat Atara Biotherapeutics' return on equity.
Atara Biotherapeutics received 429 more outperform votes than Quince Therapeutics when rated by MarketBeat users.
Summary
Quince Therapeutics beats Atara Biotherapeutics on 7 of the 13 factors compared between the two stocks.
Get Quince Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quince Therapeutics Competitors List
Related Companies and Tools
